404 related articles for article (PubMed ID: 24335104)
1. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
[TBL] [Abstract][Full Text] [Related]
2. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.
Perroud C; Thurian D; Andres M; Künzi A; Wiedemann G; Zeerleder S; Bacher U; Pabst T; Banz Y; Porret N; Rebmann E
Hematol Oncol; 2023 Dec; 41(5):912-921. PubMed ID: 37452600
[TBL] [Abstract][Full Text] [Related]
3. RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Smith D; Armenteros E; Percy L; Kumar M; Lach A; Herledan G; Stubbs M; Downward J; Yong K
Br J Haematol; 2015 Jun; 169(6):905-8. PubMed ID: 25580780
[No Abstract] [Full Text] [Related]
4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
5. Activating
Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
[No Abstract] [Full Text] [Related]
6. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E;
Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376
[TBL] [Abstract][Full Text] [Related]
7. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
9. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
10. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Chesi M; Bergsagel PL
Int J Hematol; 2013 Mar; 97(3):313-23. PubMed ID: 23456262
[TBL] [Abstract][Full Text] [Related]
12. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
13. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
14. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
15. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
16. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Lichter DI; Danaee H; Pickard MD; Tayber O; Sintchak M; Shi H; Richardson PG; Cavenagh J; Bladé J; Façon T; Niesvizky R; Alsina M; Dalton W; Sonneveld P; Lonial S; van de Velde H; Ricci D; Esseltine DL; Trepicchio WL; Mulligan G; Anderson KC
Blood; 2012 Nov; 120(23):4513-6. PubMed ID: 23018640
[TBL] [Abstract][Full Text] [Related]
17. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Ailawadhi S; Miecznikowski J; Gaile DP; Wang D; Sher T; Mulligan G; Bryant B; Wilding GE; Mashtare T; Stein L; Masood A; Neuwirth R; Lee KP; Chanan-Khan A
Leuk Lymphoma; 2012 Jun; 53(6):1174-82. PubMed ID: 22054286
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]